National Vision Holdings, Inc. (EYE) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Latest close $17.60 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
First Eagle Investment Management — 1 tracked fund hold EYE. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
ALCON INC (ALC) · COOPER COMPANIES, INC. (COO) · Warby Parker Inc. (WRBY) · Bausch & Lomb Corp (BLCO) · THERMO FISHER SCIENTIFIC INC. (TMO) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| First Eagle Investment Management | 0.01% | 429,618 | ADDED (+93.9%) Q3 filed Nov 10 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -8.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 233 of 8,857 filers |
| Long-only filers among them | 231 |
| Change vs 2026 Q1 | -15 net · 229 entered · 244 exited |
| Shares reported, all filers | 99,478,888 |
| Reported value, all filers | $1.9B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Ophthalmic Goods (SIC 3851) |
| Revenue · FY2026 | $2.0B |
| Net income · FY2026 | $29.6M |
| Total assets · FY2026 | $2.0B |
| Shares outstanding | 79,069,313 |
| Market cap (at latest close) | $1.4B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 15,740,393 |
| Share of shares outstanding | 19.91% |
| Days to cover | 9.68 |
Shares short at recent settlements — Jul 31, 2026: 14.3M · Aug 14, 2026: 14.1M · Aug 31, 2026: 14.1M · Sep 15, 2026: 15.7M · Sep 30, 2026: 15.5M · Oct 15, 2026: 15.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 201 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | Wilkes Alexander | Officer, Director | 35,000 | $955.5K | Mar 11, 2026 | SEC filing |
| Mar 6, 2026 | FAHS L READE | Member of immediate family of any of the foregoing | 4,071 | $120.4K | Mar 6, 2026 | SEC filing |
| Mar 6, 2026 | FAHS L READE | Officer, Director | 7,601 | $224.9K | Mar 6, 2026 | SEC filing |
| Sep 16, 2025 | FAHS L READE | Officer, Director | 10,598 | $253.6K | Sep 16, 2025 | SEC filing |
| Sep 15, 2025 | FAHS L READE | Officer, Director | 2,002 | $47.7K | Sep 15, 2025 | SEC filing |
| Aug 28, 2025 | FAHS L READE | Officer, Director | 137,400 | $3.3M | Aug 28, 2025 | SEC filing |
| May 16, 2025 | Moore Patrick R. | Former Officer | 15,983 | $305.8K | May 16, 2025 | SEC filing |
| May 15, 2025 | Molony Megan | Officer | 10,581 | $196.8K | May 15, 2025 | SEC filing |
| May 14, 2025 | Molony Megan | Officer | 3,900 | $73.7K | May 14, 2025 | SEC filing |
| May 13, 2025 | Acharya Ravi | Officer | 12,000 | $225.1K | May 13, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Wellington Management Group LLP | SC 13G/A | 7,669,853 | 9.6% | Jun 30, 2026 | SEC filing |
| Aug 6, 2026 | Wellington Management Group LLP | SC 13G/A | 8,338,927 | 10.4% | Jul 31, 2026 | SEC filing |
| Aug 6, 2026 | FMR LLC | SC 13G | 4,070,391.74 | 5.1% | Jun 30, 2026 | SEC filing |
| Jul 31, 2026 | Vanguard Capital Management | SC 13G/A | 3,994,686 | 5.0% | Jun 30, 2026 | SEC filing |
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 4,020,142 | 5.1% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Portfolio Management | SC 13G | 5,781,797 | 7.3% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 13, 2026 | American Century Investment Management, Inc. | SC 13G/A | 3,580,367 | 4.5% | Dec 31, 2025 | SEC filing |
| Feb 10, 2026 | Wellington Management Group LLP | SC 13G/A | 5,783,699 | 7.3% | Dec 31, 2025 | SEC filing |
| Nov 14, 2025 | Fund 1 Investments, LLC | SC 13G/A | 358,800 | 0.5% | Sep 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Ophthalmic Goods (SIC 3851). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 214 Lobbying Disclosure Act filings named this company as client, 2000–2026; most common issues: Health Issues (113), Budget/Appropriations (103), Medical/Disease Research/Clinical Labs (69).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
Key figures
· Cash Flow (FCF) — Latest FCF: $73.5M · FCF yield: 5.5% · Positive FCF years: 3
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 3 of the last 20 quarterly lists; latest 2024 Q2, ranked #38 of 50.
Also held by the tracked funds that hold EYE — ranked by lift, the co-holding pattern described in Methodology: ALCON INC (ALC) · COOPER COMPANIES, INC. (COO) · Warby Parker Inc. (WRBY) · Bausch & Lomb Corp (BLCO) · THERMO FISHER SCIENTIFIC INC. (TMO) · INTUITIVE SURGICAL INC (ISRG) · Medtronic plc (MDT) · WATERS CORP /DE/ (WAT).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 12, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 12, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Jun 22, 2026 | 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
ALCON INC (ALC) · Track Record: how the signals scored · Practice timing on EYE
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.